Doctor promotes new lung surgery technique

Jul 02, 2007

A surgeon at the University of Cincinnati says medical schools should integrate minimally invasive lung surgery into their training programs.

A report by Dr. Michael Reed, assistant professor of surgery at UC and a thoracic surgeon at University Hospital, said the procedure --known as a thoracoscopic lobectomy-- is done through several small incisions and results in faster recovery time and less pain for patients.

"Thoracoscopic lobectomy should be considered the standard of care for patients with early-stage lung cancers," Reed said Friday in a release. "But few surgeons offer the procedure because it's difficult and requires a lot of additional training."

The university said about 10 percent of all lung cancer operations nationwide are done with minimally invasive techniques, but more than half the patients who need the surgery would qualify for the less invasive procedure, which results in faster recovery time and less pain for patients.

Reed said about 75 percent of all lobectomies at University Hospital are now done using the minimally invasive approach.

He presented the findings of his report Friday at the Western Thoracic Surgical Association's annual meeting in Santa Ana Pueblo, N.M.

Copyright 2007 by United Press International

Explore further: New drug sales help boost Novartis Q1 profit (Update)

add to favorites email to friend print save as pdf

Related Stories

CSI for invasive species

Nov 25, 2013

(Phys.org) —Several Canadian biologists, including two at Simon Fraser University, are breathing a collective sigh of relief after learning that a monstrous fish found in a Burnaby, B.C. pond is not a northern ...

New compound prevents first steps of fungal infection

Aug 13, 2013

Targeting serious and sometimes deadly fungal infections, a team of researchers at Worcester Polytechnic Institute (WPI) and the University of Massachusetts Medical School (UMMS) has discovered a chemical ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Google+ boss leaving the company

The executive credited with bringing the Google+ social network to life is leaving the Internet colossus after playing a key role there for nearly eight years.